Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

BACKGROUND: On the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ESMO Open
Glavni autori: Orditura, Michele, Gravina, Adriano, Riccardi, Ferdinando, Diana, Anna, Mocerino, Carmela, Leopaldi, Luigi, Fabozzi, Alessio, Giordano, Guido, Nettuno, Raffaele, Incoronato, Pasquale, Barzelloni, Maria Luisa, Caputo, Roberta, Pisano, Agata, Grimaldi, Giuseppe, Genua, Geppino, Montesarchio, Vincenzo, Barbato, Enrico, Iodice, Giovanni, Lieto, Eva, Procaccini, Eugenio, Mabilia, Roberto, Febbraro, Antonio, Laurentiis, Michelino De, Ciardiello, Fortunato
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2017
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519815/
https://ncbi.nlm.nih.gov/pubmed/28761747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000176
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Učitavanje...

Similar Items